Psychopharmacology

Researchers performed a head-to-head trial of vortioxetine versus desvenalfaxine in patients with depression and partial response to SSRIs.

The trial’s results showed statistically significant reductions in all major symptom domains and secondary endpoints.

The experts weighed in on a wide variety of psychiatric issues for the October 2023 issue of Psychiatric Times.

Here are some updates from the world of psychiatry throughout the month of October.

What are the treatment options for insomnia when avoiding benzodiazepines? John W. Winkelman MD, PhD, shares insights and guidance at the 2023 Annual Psychiatric Times World CME Conference.

From long-acting injectable antipsychotics for managing schizophrenia to mental health responses to the recent conflict in Israel, here are highlights from the week in Psychiatric Times.

"Cumulatively, the findings of such reports have led to a concerted effort to encourage physicians to monitor patients for manic symptoms on initiation, reintroduction, and dose modulation of corticosteroid therapy."

What is the risk of diabetes, hypertension, or hyperlipidemia with antipsychotic polypharmacy in patients with schizophrenia? Researchers investigated these associations in a population-based prospective cohort study.

Following a long path to approval, gepirone hydrochloride extended-release tablets (Exxua) is the first FDA-approved medication with this novel mechanism of action for adults with MDD.

“Are my other medications making my depression worse?” Researchers investigated associations between medications with potential depressive symptom adverse effects and the level of depressive symptoms in a large survey study.

According to the National Community Pharmacists Association, 97% of independent pharmacy owners reported shortages of Adderall in early 2023. As these shortages continue, here's how you can best support your patients with ADHD.

What risk does clomiphene use present to patients?

Data showed good news for safety and tolerability with mixed good news for efficacy.

Session at the 2023 American Psychiatric Association Annual Meeting shares insights on REMS for psychiatric medications.

From new FDA treatment approvals to choosing the right levels of care in crisis stabilization units, here are highlights from the week in Psychiatric Times.

The risperidone formulation is the first FDA-approved treatment for this patient population to use technology enabling controlled release over time.

Treatment is now the first and only once-at-bedtime oxybate to be approved by the FDA for individuals with narcolepsy.

A gut feeling? Researchers analyzed the gut microbiome in major depression disorder and its modulation by SSRI antidepressants.

From collaborative care for individuals with schizophrenia and COVID-19 to strategies for building patient rapport, here are highlights from the week in Psychiatric Times.

From an update on at-home ketamine therapy to the psychopharmacologic treatment of bipolar depression, here are highlights from the week in Psychiatric Times.

From Alzheimer disease treatments to the psychiatric implications of conspiracy theories, here are highlights from the week in Psychiatric Times.

Researchers performed a nationwide register-based cohort study of patients treated with lithium in Finland.

"There are a number of themes in my book, and one of them is to subtly bust the myth that people who get diagnosed with serious mental illness cannot recover."

From the impact of patients’ overdose deaths on physicians to addressing America’s mental health crisis, here are highlights from the week in Psychiatric Times.

"The history of medicine is rich in blaming the disease or the patient for 'untreatable' symptoms, until we stumble upon or develop a treatment that is, in fact, effective."

The experts weighed in on a wide variety of psychiatric issues for the January 2023 issue of Psychiatric Times.

From a new FDA approval to treating “New Year depression” in patients, here are highlights from the week in Psychiatric Times.

Data on the effects of discontinuing lithium on renal function are scarce and conflicting. A new study exploring these effects may aid in the clinical decision-making process.

We remain challenged to improve treatments and outcomes in schizophrenia. Explore the latest options.